Screener
D&A at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Nektar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:DepreciationAndAmortization.
The source filing: Nektar Therapeutics’s 10-Q, filed May 8, 2026.
- Filed
- May 7, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-212596
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Non-cash interest expense on liabilities related to the sales of future royalties | 7,942 | 4,974 |
| Loss from equity method investment | 1,750 | 4,461 |
| Stock-based compensation | 3,355 | 3,898 |
| Depreciation and amortization | 151 | 426 |
| Amortization of premiums (discounts), net | (1,663) | (1,324) |
| Changes in operating assets and liabilities: | ||
| Operating leases, net | (2,409) | (1,813) |
| Other assets | 949 | (5,958) |
Item 1. Condensed Consolidated Financial Statements—Unaudited:
FAQ
- What is Nektar Therapeutics's D&A?
- Nektar Therapeutics (NKTR) reported D&A of $151K in Q1 2026.
- How has Nektar Therapeutics's D&A changed year-over-year?
- Nektar Therapeutics's D&A decreased by 64.6% year-over-year, from $426K to $151K.
- What is the long-term trend for Nektar Therapeutics's D&A?
- Over 4 years (2021 to 2025), Nektar Therapeutics's D&A has grown at a -48.1% compound annual growth rate (CAGR), from $14.15M to $1.03M.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about Nektar Therapeutics's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude